SillaJen Biotherapeutics, Inc. is a clinical-stage company focused on developing and commercializing oncolytic immunotherapy products for cancer. Our lead product Pexa-Vec is being evaluated in a multinational Phase 3 clinical trial (PHOCUS) in patients with advanced liver cancer, also known as hepatocellular carcinoma (HCC).
SillaJen Biotherapeutics, Inc. was formerly known as Jennerex, Inc.; we were acquired in 2014 by SillaJen, Inc., a privately-held Korean biotechnology company, and subsequently changed our name to reflect the new ownership. SillaJen Biotherapeutics is located in San Francisco and is responsible for manufacturing, regulatory affairs, alliance management, clinical operations and accounting for clinical trials. The parent company has responsibility for finance, management, legal operations and R&D and has offices in Busan and Seoul, Korea.